<DOC>
	<DOCNO>NCT02157142</DOCNO>
	<brief_summary>The purpose study evaluate safety performance HLT System patient severe aortic stenosis present High Risk aortic valve replacement surgery .</brief_summary>
	<brief_title>HLT transfemOral Replacement aortIc Valve Via transcatherteriZatiON</brief_title>
	<detailed_description />
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . 75 year age old 2 . Echocardiographic hemodynamic base evidence calcific ( senile ) aortic stenosis one following : aortic valve EOA &lt; 1.0 cm2 0.6 cm2/m2 , mean aortic valve gradient &gt; 40 mmHg peak aortic valve velocity &gt; 4 m/sec 3 . Symptomatology due aortic stenosis result New York Heart Association ( NYHA ) Functional Classification II great 4 . Aortic valve annular diameter ≥ 21 ≤23mm measure MSCT 5 . An STS score ≥10 ; Logistic EuroScore I ≥ 15 ; determination one cardiovascular surgeon one cardiologist comorbidities capture STS EuroScore expect increase operative mortality risk &gt; 15 % . 6 . Geographically available , willing comply follow able provide write informed consent 1 . Congenital unicuspid bicuspid aortic valve , noncalcified aortic valve ; valve eccentricity ( calcific otherwise ) opinion investigator could compromise procedural success . 2 . Preexisting prosthetic heart valve position , prosthetic ring 3 . Severe ( Grade 3 4 ) aortic , mitral tricuspid valve regurgitation 4 . Moderate severe mitral stenosis 5 . Myocardial infarction within past 30 days* 6 . Echocardiographic evidence intracardiac mass , thrombus vegetation 7 . LVEF &lt; 30 % 8 . Uncontrolled hypertension ( i.e . blood pressure baseline &gt; 140 mmHg systolic ; opinion investigator control medical therapy ) . 9 . Severe pulmonary hypertension pulmonary systolic pressure great twothirds systemic pressure 10 . Hemodynamic instability require inotropic drug therapy within past 14 day mechanical support within past 6 months* 11 . Untreated clinically significant coronary artery disease require revascularization 12 . Presence significant aortic disease atheroma , thrombus , aneurysm , opinion investigator , preclude safe implant delivery 13 . Blood dyscrasia define : acute leukopenia , acute anemia , acute thrombocytopenia , history bleed diathesis coagulopathy 14 . Patient ineligible refuse blood transfusion 15 . Unfavorable peripheral vascular anatomy disease ( e.g . severe obstructive calcification , severe tortuosity small vessel ) would preclude passage catheter femoral arterial access aorta evidence peripheral MSCT 16 . Active peptic ulcer gastrointestinal bleeding within past 90 days* 17 . Stroke transient ischemic attack within past 6 months* 18 . Renal insufficiency demonstrate serum creatinine &gt; 2.5 mg/dL end stage renal disease require chronic dialysis 19 . Active infection require ongoing treatment 20 . Need emergent surgery intervention investigational procedure 21 . Any therapeutic invasive cardiac procedure perform plan perform within 30 day index procedure , ( 6 month drug elute coronary stent biventricular pacemaker implantation ) * 22 . Hypersensitivity contraindication procedural medication device material ( e.g . titanium , nickel , pork ) adequately premedicated 23 . Life expectancy &lt; 1 year due noncardiac comorbid condition 24 . Currently participate investigational drug device study may confound result study 25 . History cognitive mental health status would interfere study participation `` * '' At time procedure , subject 's medical status change since enrollment , subject shall reevaluate eligibility .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Severe aortic stenosis</keyword>
	<keyword>Aortic valve stenosis</keyword>
	<keyword>Transcatheter aortic valve replacement</keyword>
</DOC>